WEBULL
News
ATRA
4.880
+8.20%
0.370
Weekly Report: what happened at ATRA last week (0126-0130)?
Weekly Report · 5d ago
Weekly Report: what happened at ATRA last week (0119-0123)?
Weekly Report · 01/26 10:16
Tabelecleucel’s Phase 3 EBV+ PTLD Trial Progress Signals Continued Potential for Atara Biotherapeutics
TipRanks · 01/19 16:30
Weekly Report: what happened at ATRA last week (0112-0116)?
Weekly Report · 01/19 10:22
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 01/15 17:05
Panacea Innovation Ltd Sells Common Shares of Atara Biotherapeutics Inc
Reuters · 01/15 02:16
Atara Biotherapeutics Cut to Hold From Buy by Canaccord Genuity
Dow Jones · 01/13 20:28
Atara Biotherapeutics Price Target Cut to $6.00/Share From $25.00 by Canaccord Genuity
Dow Jones · 01/13 20:28
Canaccord Genuity Downgrades Atara Biotherapeutics to Hold, Lowers Price Target to $6
Benzinga · 01/13 20:17
Atara Biotherapeutics downgraded to Hold from Buy at Canaccord (earlier)
TipRanks · 01/13 18:40
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 01/13 17:05
Atara Biotherapeutics Stock Falls After FDA CRL On EBVALLO BLA
NASDAQ · 01/13 02:20
FDA Rejects Atara’s EBVALLO BLA, Commercial Path Uncertain
TipRanks · 01/12 21:40
Atara plummets on FDA Complete Response Letter for tabelecleucel
Seeking Alpha · 01/12 17:42
Gold Rises Sharply; Lyra Therapeutics Shares Plunge
Benzinga · 01/12 17:26
Monday Sector Laggards: Biotechnology, Credit Services & Lending Stocks
NASDAQ · 01/12 17:08
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 01/12 17:05
FDA Rejects Atara Biotherapeutics' Cell Therapy Again, Stock Sinks
Benzinga · 01/12 16:06
BUZZ-U.S. STOCKS ON THE MOVE-AbCellera Biologics, Zymeworks, Silver miners
Reuters · 01/12 15:40
Atara Biotherapeutics Stock Falls After Surprise FDA Refusal to Approve Ebvallo
Dow Jones · 01/12 15:24
More
Webull provides a variety of real-time ATRA stock news. You can receive the latest news about Atara Biotherape through multiple platforms. This information may help you make smarter investment decisions.
About ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.